Histopathological evidence for an association of inflammation with ductal pin-like lesions but not with ductal adenocarcinoma in the prostate of the noble rat

Prostate

Volumn 68, Issue 7, 2008, Pages 728-739

  Bernoulli, Jenni ^a   Yatkin, Emrah ^a,b   Laakso, Arto ^a   Anttinen, Mikael ^a   Bosland, Maarten ^c,d   Vega, Katherine ^d   Kallajoki, Markku ^a   Santti, Risto ^a   Pylkkänen, Liisa ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b ISTANBUL UNIVERSITY   (Turkey)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model; Prostate cancer; Prostate inflammation; Prostatic intraepithelial neoplasia; Sex steroid

Indexed keywords

ESTRADIOL; TESTOSTERONE;

ANDROGEN DEFICIENCY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CHRONIC INFLAMMATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG IMPLANT; ESTROGEN DEFICIENCY; HISTOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RAT; TISSUE INJURY; TREATMENT DURATION; URETHRA;

ANIMALS; CARCINOMA, DUCTAL; DISEASE MODELS, ANIMAL; DRUG IMPLANTS; ESTRADIOL; MALE; ORGAN SIZE; PRECANCEROUS CONDITIONS; PROLACTIN; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROSTATITIS; RATS; RATS, INBRED STRAINS; TESTOSTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 41549137764     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20719     Document Type: Article

References (45)

1. MacLennan GT, Eisenberg R, Fleshman RL, Taylor JM, Fu P, Resnick MI, Gupta S. The influence of chronic inflammation in prostatic carcinogenesis: A 5-year followup study. J Urol 2006; 176(3):1012-1016.
2. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, Nelson WG. Prostate carcinogenesis and inflammation: Emerging insights. Carcinogenesis 2005;26(7):1170-1181.
3. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004;172(5 Pt 2):S6-11 discussion; S11-S12.
4. Ho E, Boileau TW, Bray TM. Dietary influences on endocrine-inflammatory interactions in prostate cancer development. Arch Biochem Biophys 2004;428(1):109-117.
5. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-269.
6. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002;60(1):78-83.
7. Barqawi A, Thompson IM, Crawford ED. Prostate cancer chemoprevention: An overview of United States trials. J Urol 2004;171(2 Pt 2):S5-8 discussion; S9.
8. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol 1999;155(6):1985-1992.
9. Ruska KM, Sauvageot J, Epstein JI. Histology and cellular kinetics of prostatic atrophy. Am J Surg Pathol 1998;22(9):1073-1077.
10. Putzi MJ, De Marzo AM. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 2000;56(5):828-832.
11. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003;361(9361): 955-964.
12. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349(4):366-381.
13. Shirai T, Takahashi S, Cui L, Futakuchi M, Kato K, Tamano S, Imaida K. Experimental prostate carcinogenesis - Rodent models. Mutat Res 2000;462(2-3):219-226.
14. Bostwick DG, Qian J. High-grade prostatic intraepithelial neoplasia. Mod Pathol 2004;17(3):360-379.
15. Bostwick DG, Ramnani D, Qian J. Prostatic intraepithelial neoplasia: Animal models 2000. Prostate 2000;43(4):286-294.
16. Noble RL. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 1977;37(6):1929-1933.
17. Bosland MC, Ford H, Horton L. Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd: SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol. Carcinogenesis 1995; 16(6):1311-1317.
18. Vykhovanets EV, Resnick MI, MacLennan GT, Gupta S. Experimental rodent models of prostatitis: Limitations and potential. Prostate Cancer Prostatic Dis 2007;10(1):15-29.
19. Gilardoni MB, Rabinovich GA, Oviedo M, Depiante-Depaoli M. Prostate cancer induction in autoimmune rats and modulation of T cell apoptosis. J Exp Clin Cancer Res 1999;18(4):493-504.
20. Bernoulli J, Yatkin E, Talvitie EM, Santti R, Streng T. Urodynamic changes in a noble rat model for nonbacterial prostatic inflammation. Prostate 2007;67(8):888-899.
21. Nickel JC, True LD, Krieger JN, Berger RE, Boag AH, Young ID. Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int 2001; 87(9):797-805.
22. Sakr WA, Partin AW. Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia. Urology 2001;57 (4 Suppl 1):115-120.
23. Montironi R, Vela Navarrete R, Lopez-Beltran A, Mazzucchelli R, Mikuz G, Bono AV. Histopathology reporting of prostate needle biopsies. 2005 Update. Virchows Arch 2006;449(1):1-13.
24. Kwong J, Lui K, Chan PS, Ho SM, Wong YC, Xuan JW, Chan FL. Expression study of three secretory proteins (prostatic secretory protein of 94 amino acids, probasin, and seminal vesicle secretion II) in dysplastic and neoplastic rat prostates. Prostate 2003;56(2):81-97.
25. Ofner P, Bosland MC, Vena RL. Differential effects of diethyl-stilbestroland estradiol-17beta in combination with testosterone on rat prostate lobes. Toxicol Appl Pharmacol 1992;112(2):300-309.
26. Leav I, Ho SM, Ofner P, Merk FB, Kwan PW, Damassa D. Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. J Natl Cancer Inst 1988;80(13):1045-1053.
27. Bosland MC. The role of estrogens in prostate carcinogenesis: A rationale for chemoprevention. Rev Urol 2005;7 (Suppl 3):S4-S10.
28. Lane KE, Leav I, Ziar J, Bridges RS, Rand WM, Ho SM. Suppression of testosterone and estradiol-17beta-induced dysplasia in the dorsolateral prostate of Noble rats by bromocriptine. Carcinogenesis 1997;18(8):1505-1510.
29. Lucia MS, Torkko KC. Inflammation as a target for prostate cancer chemoprevention: Pathological and laboratory rationale. J Urol 2004;171(2 Pt 2):S30-34. discussion S35.
30. Kim R, Emi M, Tanabe K. Cancer immunosuppression and autoimmune disease: Beyond immunosuppressive networks for tumour immunity. Immunology 2006;119(2):254-264.
31. Adler AJ. Mechanisms of T cell tolerance and suppression in cancer mediated by tumor-associated antigens and hormones. Curr Cancer Drug Targets 2007;7(1):3-14.
32. Lane KE, Ricci MJ, Ho SM. Effect of combined testosterone and estradiol-17 beta treatment on the metabolism of E2 in the prostate and liver of noble rats. Prostate 1997;30(4):256-262.
33. Wang YZ, Wong YC. Sex hormone-induced prostatic carcinogenesis in the noble rat: The role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate 1998;35(3):165-177.
34. Yatkin E, Streng T, Kauppila ML, Bernoulli J, Saarinen N, Santti R. The soy effect in the disease models of nonbacterial prostatitis and obstructive voiding. Exp Biol Med (Maywood) 2007;232(5): 674-681.
35. Sharma OP, Adlercreutz H, Strandberg JD, Zirkin BR, Coffey DS, Ewing LL. Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. J Steroid Biochem Mol Biol 1992;43(6):557-564.
36. Bosland MC, Kato I, Melamed J, Taneja S, Lepor H, Torre P, Walden P, Zeleniuch-Jacquotte A, Lumey LH. Chemoprevention trials in men with prostate-specific antigen failure or at high risk for recurrence after radical prostatectomy: Application to efficacy assessment of soy protein. Urology 2001;57 (4 Suppl 1):202-204.
37. Kurahashi N, Iwasaki M, Sasazuki S, Otani T, Inoue M, Tsugane S. Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol Biomarkers Prev 2007;16(3):538-545.
38. Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The Adventist health study (United States). Cancer Causes Control 1998;9(6):553-557.
39. Thompson CJ, Tam NN, Joyce JM, Leav I, Ho SM. Gene expression profiling of testosterone and estradiol-17 beta-induced prostatic dysplasia in Noble rats and response to the antiestrogen ICI 182,780. Endocrinology 2002;143(6):2093- 2105.
40. Pylkkanen L, Santti R, Newbold R, McLachlan JA. Regional differences in the prostate of the neonatally estrogenized mouse. Prostate 1991;18(2):117-129.
41. Pylkkanen L, Makela S, Valve E, Harkonen P, Toikkanen S, Santti R. Prostatic dysplasia associated with increased expression of c-myc in neonatally estrogenized mice. J Urol 1993;149(6):1593-1601.
42. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: Current perspectives and future directions. Prostate 2002;52(3):213-235.
43. Raynaud JP. Prostate cancer risk in testosterone-treated men. J Steroid Biochem Mol Biol 2006;102(1-5):261-266.
44. Gould DC, Kirby RS. Testosterone replacement therapy for late onset hypogonadism: What is the risk of inducing prostate cancer? Prostate Cancer Prostatic Dis 2006;9(1):14-18.
45. Kaufman JM. The effect of androgen supplementation therapy on the prostate. Aging Male 2003;6(3):166-174.